425 related articles for article (PubMed ID: 22327882)
41. Targeting tumor-related immunosuppression for cancer immunotherapy.
Frumento G; Piazza T; Di Carlo E; Ferrini S
Endocr Metab Immune Disord Drug Targets; 2006 Sep; 6(3):233-7. PubMed ID: 17017974
[TBL] [Abstract][Full Text] [Related]
42. Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity.
Kalim KW; Yang JQ; Wunderlich M; Modur V; Nguyen P; Li Y; Wen T; Davis AK; Verma R; Lu QR; Jegga AG; Zheng Y; Guo F
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36427906
[TBL] [Abstract][Full Text] [Related]
43. Targeting Treg cells in cancer immunotherapy.
Tanaka A; Sakaguchi S
Eur J Immunol; 2019 Aug; 49(8):1140-1146. PubMed ID: 31257581
[TBL] [Abstract][Full Text] [Related]
44. Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity.
Yano H; Andrews LP; Workman CJ; Vignali DAA
Immunology; 2019 Jul; 157(3):232-247. PubMed ID: 31087644
[TBL] [Abstract][Full Text] [Related]
45. Tregs and rethinking cancer immunotherapy.
Curiel TJ
J Clin Invest; 2007 May; 117(5):1167-74. PubMed ID: 17476346
[TBL] [Abstract][Full Text] [Related]
46. Regulatory circuits of T cell function in cancer.
Speiser DE; Ho PC; Verdeil G
Nat Rev Immunol; 2016 Oct; 16(10):599-611. PubMed ID: 27526640
[TBL] [Abstract][Full Text] [Related]
47. Single-Cell Sequencing Reveals the Transcriptome and TCR Characteristics of pTregs and
Hui Z; Zhang J; Zheng Y; Yang L; Yu W; An Y; Wei F; Ren X
Front Immunol; 2021; 12():619932. PubMed ID: 33868236
[TBL] [Abstract][Full Text] [Related]
48. CD25+ CD4+ regulatory T-cells in cancer.
Linehan DC; Goedegebuure PS
Immunol Res; 2005; 32(1-3):155-68. PubMed ID: 16106066
[TBL] [Abstract][Full Text] [Related]
49. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
50. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
Wang H; Franco F; Ho PC
Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
[TBL] [Abstract][Full Text] [Related]
51. Depletion of CD4(+)CD25(high) regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy.
Xu L; Xu W; Jiang Z; Zhang F; Chu Y; Xiong S
Cancer Biol Ther; 2009 Jan; 8(1):66-72. PubMed ID: 19029829
[TBL] [Abstract][Full Text] [Related]
52. Function of CD4+,CD25+ Treg cells in MRL/lpr mice is compromised by intrinsic defects in antigen-presenting cells and effector T cells.
Parietti V; Monneaux F; Décossas M; Muller S
Arthritis Rheum; 2008 Jun; 58(6):1751-61. PubMed ID: 18512811
[TBL] [Abstract][Full Text] [Related]
53. CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1.
Han Y; Guo Q; Zhang M; Chen Z; Cao X
J Immunol; 2009 Jan; 182(1):111-20. PubMed ID: 19109141
[TBL] [Abstract][Full Text] [Related]
54. Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responses.
Oh DS; Kim H; Oh JE; Jung HE; Lee YS; Park JH; Lee HK
Oncotarget; 2017 Jul; 8(29):47440-47453. PubMed ID: 28537894
[TBL] [Abstract][Full Text] [Related]
55. CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model.
Elpek KG; Lacelle C; Singh NP; Yolcu ES; Shirwan H
J Immunol; 2007 Jun; 178(11):6840-8. PubMed ID: 17513732
[TBL] [Abstract][Full Text] [Related]
56. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
Kumar P; Saini S; Prabhakar BS
Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
[TBL] [Abstract][Full Text] [Related]
57. Mesenchymal stem cell effects on T-cell effector pathways.
Duffy MM; Ritter T; Ceredig R; Griffin MD
Stem Cell Res Ther; 2011 Aug; 2(4):34. PubMed ID: 21861858
[TBL] [Abstract][Full Text] [Related]
58. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Ohue Y; Nishikawa H
Cancer Sci; 2019 Jul; 110(7):2080-2089. PubMed ID: 31102428
[TBL] [Abstract][Full Text] [Related]
59. T Regulatory Cell Subpopulations Associated with Recent Ultraviolet Radiation Exposure in a Skin Cancer Screening Cohort.
Hesterberg RS; Amorrortu RP; Zhao Y; Hampras S; Akuffo AA; Fenske N; Cherpelis B; Balliu J; Vijayan L; Epling-Burnette PK; Rollison DE
J Immunol; 2018 Dec; 201(11):3269-3281. PubMed ID: 30389774
[TBL] [Abstract][Full Text] [Related]
60. Unlocking the Complexities of Tumor-Associated Regulatory T Cells.
Chao JL; Savage PA
J Immunol; 2018 Jan; 200(2):415-421. PubMed ID: 29311383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
